Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGFBP5 | P24593 | 6/20 | 0.42 |
| ▸ | IGFBP3 | P17936 | 6/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | IGFBP1 | P08833 | 1/20 | 0.35 |
| ▸ | IGFBP2 | P18065 | 1/20 | 0.35 |
| ▸ | IGFBP4 | P22692 | 1/20 | 0.35 |
| ▸ | IGFBP6 | P24592 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9340031 | 0.89 | IGFBP3 (0.40) | IGFBP5IGFBP3ALOX15TSHRHIF1A | |
| SCHEMBL9340864 | 0.82 | IGFBP5 (0.39) | IGFBP5IGFBP3ALOX15TSHRMAPT | |
| SCHEMBL9343878 | 0.82 | ALOX15 (0.43) | IGFBP5IGFBP3ALOX15KDM4EMAPT | |
| 7-Chlorokynurenic Acid SCHEMBL157187 | 0.81 | IGFBP3 (0.47) | IGFBP5IGFBP3HIF1A | |
| 7-Chlorokynurenic Acid SCHEMBL31238955 | 0.81 | IGFBP3 (0.47) | IGFBP5IGFBP3HIF1A | |
| 7-Chlorokynurenic Acid SCHEMBL29386783 | 0.81 | IGFBP3 (0.47) | IGFBP5IGFBP3HIF1A | |
| SCHEMBL2905794 | 0.80 | IGFBP5 (0.46) | IGFBP5IGFBP3ALOX15TSHRHIF1A | |
| 7-Chlorokynurenic Acid SCHEMBL20770380 | 0.79 | IGFBP3 (0.46) | IGFBP5IGFBP3HIF1A | |
| SCHEMBL2902980 | 0.79 | ALOX15 (0.47) | IGFBP5IGFBP3ALOX15TSHRHIF1A | |
| Phencyclidine SCHEMBL9118919 | 0.78 | SIGMAR1 (0.46) | HIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333369-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2017-11-23 | — | — | US | claimed |
| EP-2992877-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PAIN | Grünenthal GmbH (DE) | 2016-03-09 | — | — | EP | claimed |
| US-20140309311-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2014-10-16 | — | — | US | claimed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | claimed |
| EP-2582366-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PAIN | Grünenthal GmbH (DE) | 2013-04-24 | — | — | EP | claimed |
| WO-2011157391-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PAIN | Grünenthal GmbH (DE) | 2011-12-22 | — | — | WO | claimed |
| US-20110306674-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2011-12-15 | — | — | US | claimed |
| JP-2011526251-A | — | — | 2011-10-06 | — | — | JP | claimed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | claimed |
| EP-2310386-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2011-04-20 | — | — | EP | claimed |
| WO-2007017764-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS WITH DUAL NOS INHIBITORY ACTIVITY AND MUOPIOID AGONIST ACTIVITY | NEURAXON, INC. (CA) | 2007-02-15 | — | — | WO | claimed |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-16 | — | — | US | claimed |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2006-07-20 | — | — | US | claimed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | claimed |
| WO-2004039371-A2 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF NEUROPATHIC PAIN | PHARMACIA CORPORATION (US) | 2004-05-13 | — | — | WO | claimed |
| US-20040082543-A1 | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | claimed |
| WO-1995028081-A1 | ADDRESSING BAIT AVERSION BY DISRUPTING ASSOCIATIVE LEARNING | THE MEAT INDUSTRY RESEARCH INSTITUTE OF NEW ZEALAND INC. (NZ) | 1995-10-26 | — | — | WO | claimed |
| EP-0486586-B1 | KYNURENIC ACID DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FIDIA SPA (IT) | 1994-06-08 | — | — | EP | claimed |
| EP-0486586-A1 | KYNURENIC ACID DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | FIDIA SPA (IT) | 1992-05-27 | — | — | EP | claimed |
| WO-1991001973-A1 | KYNURENIC ACID DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FIDIA S.P.A. (IT) | 1991-02-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | IGFBP5 1734/4885IGFBP3 2098/4885ALOX15 420/4885 |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NOS2, NOS1, NOS3 | IGFBP5 1734/4885IGFBP3 2098/4885ALOX15 420/4885 |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | CNR2, CNR1, PTGS2 | IGFBP5 3932/4885IGFBP3 3653/4885ALOX15 54/4885 |
| US-20040082543-A1 | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain | GRIN2A, GRIN2B, GRIN3A | IGFBP5 4693/4885IGFBP3 4734/4885ALOX15 161/4885 |
| US-20110306674-A1 | Pharmaceutical Combination | GRIN3A, GRIN2B, GRIN2C | IGFBP5 4675/4885IGFBP3 4520/4885ALOX15 1083/4885 |
| US-20170333369-A1 | Pharmaceutical Combination | GRIN3A, GRIN2B, GRIN2C | IGFBP5 4675/4885IGFBP3 4520/4885ALOX15 1083/4885 |
| US-20140309311-A1 | Pharmaceutical Combination | GRIN3A, GRIN2B, GRIN2C | IGFBP5 4675/4885IGFBP3 4520/4885ALOX15 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.